日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip

一项针对膝关节或髋关节慢性假体关节感染患者,评估生物膜破坏性人源单克隆抗体的药代动力学和临床概念验证活性的I期研究

Conway, Janet; Delanois, Ronald E; Mont, Michael A; Stavrakis, Alexandra; McPherson, Edward; Stolarski, Edward; Incavo, Stephen; Oakes, Daniel; Salvagno, Ralph; Adams, John S; Kisch-Hancock, Adriane; Tenorio, Edgar; Leighton, Anton; Ryser, Stefan; Kauvar, Lawrence M; Bernthal, Nicholas M

Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

在 VH 框架 III 双特异性抗体形式内和作为嵌合肽设计的血清白蛋白结合旋钮结构域

Ralph Adams, Callum Joyce, Mikhail Kuravskiy, Katriona Harrison, Zainab Ahdash, Matthew Balmforth, Kelda Chia, Cinzia Marceddu, Matthew Coates, James Snowden, Emmanuel Goursaud, Karelle Ménochet, Jean van den Elsen, Richard J Payne, Alastair D G Lawson, Anthony Scott-Tucker, Alex Macpherson

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Bimekizumab,一种可中和 IL-17A 和 IL-17F 的新型人源化 IgG1 抗体

Ralph Adams, Asher Maroof, Terry Baker, Alastair D G Lawson, Ruth Oliver, Ross Paveley, Steve Rapecki, Stevan Shaw, Pavan Vajjah, Shauna West, Meryn Griffiths

Electrostatic interactions modulate the differential aggregation propensities of IgG1 and IgG4P antibodies and inform charged residue substitutions for improved developability

静电相互作用调节IgG1和IgG4P抗体的差异性聚集倾向,并为带电残基的替换提供信息,从而提高其开发性。

James T Heads ,Richard Lamb ,Sebastian Kelm ,Ralph Adams ,Peter Elliott ,Kerry Tyson ,Sarfaraj Topia ,Shauna West ,Ruodan Nan ,Alison Turner ,Alastair D G Lawson

Computational design of an epitope-specific Keap1 binding antibody using hotspot residues grafting and CDR loop swapping

使用热点残基移植和 CDR 环交换进行表位特异性 Keap1 结合抗体的计算设计

Xiaofeng Liu, Richard D Taylor, Laura Griffin, Shu-Fen Coker, Ralph Adams, Tom Ceska, Jiye Shi, Alastair D G Lawson, Terry Baker

Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling

发现一种可稳定 IL-6 和 gp80 蛋白质:蛋白质相互作用并调节其下游信号传导的连接表位抗体

Ralph Adams, Rebecca J Burnley, Chiara R Valenzano, Omar Qureshi, Carl Doyle, Simon Lumb, Maria Del Carmen Lopez, Robert Griffin, David McMillan, Richard D Taylor, Chris Meier, Prashant Mori, Laura M Griffin, Ulrich Wernery, Jörg Kinne, Stephen Rapecki, Terry S Baker, Alastair D G Lawson, Michael Wr

Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

Fab-dsFv:一种通过白蛋白结合延长血清半衰期的双特异性抗体形式

Emma Davé, Ralph Adams, Oliver Zaccheo, Bruce Carrington, Joanne E Compson, Sarah Dugdale, Michael Airey, Sarah Malcolm, Hanna Hailu, Gavin Wild, Alison Turner, James Heads, Kaushik Sarkar, Andrew Ventom, Diane Marshall, Mark Jairaj, Tim Kopotsha, Louis Christodoulou, Miren Zamacona, Alastair D Laws

Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life

通过生成人源化抗人血清白蛋白 Fv 结构域延长 fab 片段的半衰期:亲和力与血清半衰期相关性的研究

Ralph Adams, Laura Griffin, Joanne E Compson, Mark Jairaj, Terry Baker, Tom Ceska, Shauna West, Oliver Zaccheo, Emma Davé, Alastair Dg Lawson, David P Humphreys, Sam Heywood

Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

olokizumab 的发现和特性:一种靶向白细胞介素 6 并中和 gp130 信号的人源化抗体

Stevan Shaw, Tim Bourne, Chris Meier, Bruce Carrington, Rich Gelinas, Alistair Henry, Andrew Popplewell, Ralph Adams, Terry Baker, Steve Rapecki, Diane Marshall, Adrian Moore, Helen Neale, Alastair Lawson